An ongoing rise in imaging procedures, such as CT scans, PET scans, ultrasounds and MRIs has created a consistent demand for effectual contrast media injectors. Iopamidol has recently captured the attention of pharmaceutical research and development teams with an unprecedented FDA nod. At the close of November 2014 the FDA approved Iopamidol as a first and thus far only multi-dose compliant contrast medium. Designated as a breakthrough point-of care solution for usage in the CT Suite, the Iopamidol injection offers an innovative bulk pack design which minimizes adverse risk factors for patients. Additionally, the Iopamidol ISOVUE IBP presents consistently reliable safety standards, which lend to an effective and improved workflow for practitioners. Radiological procedures in the CT suite are performed across the globe at flourishing rates, leading to a swelling need for more efficacious contrast media products. A recent market research report released on January 5, 2015 predicts a steady increase in the need and utilization for contrast media injectors through 2020. The aforementioned report gleaned data from five major European markets and touted the increasing use of multi-dose contrast media worldwide.
The importance of quality imaging procedures has become a vital component of patient care. The FDA approval of Bracco’s ISOVUE IBP is the first nod to a technologically advanced form of contrast media. Advantages for practitioners utilizing this multi-dose and multi-patient contrast management system include the ability to control the amount of media via a precise injection and infusion rate, as well as greater patient safety via physician compliance. The current market for contrast media injectors, like Iopamidol, include the market application sub categories of cardiology, neurology and oncology. Products are segmented into CT, MR and angio/vascular injector categories. The Institute for Safe Medication Practices called for hospital pharmacy oversight in 2012 for the distribution, purchase, storage and use of intravenous contrast media, as well as the use of single dose vials and pre-filled syringes. The proper use of Pharmacy Bulk Packages, also known as PBPs, for radiological use was also stressed for continuous oversight and compliance by The Institute for Safe Medication Practices. The challenges facing a one size doesn’t fit all patient landscape is constantly being addressed by R&D experts in the contrast media field.
The Iopamidol ISOVUE IBP is praised for not only allowing cost-effective and targeted intravenous dosing, but also for offering 10-hour on-demand dosing from one container. Utilizing the same container for dosing eliminates the risk of multi-dose errors that are regularly associated with the transfer of contrast media outside of a hospital pharmacy setting. Future development of state of the art contrast media for improved Point-of-Care needs has become an anticipatory and prudent need around the globe. LGM Pharma can assist clients as a supplier/distributor of the API Iopamidol, CAS # 60166-93-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.